Hims & Hers
Health and wellness, personalized
Major national telehealth provider offering compounded injectable GLP-1 medications, currently facing regulatory scrutiny from Novo Nordisk lawsuit and FDA enforcement actions.
Medications Available
Pros
- Competitive pricing for compounded injectable semaglutide
- Nationwide availability
- Quick customer service response
- Month-to-month and multi-month plan flexibility
Cons
- No insurance accepted
- Compounded oral semaglutide pill suspended after FDA/DOJ intervention
- Novo Nordisk patent lawsuit filed February 2026
- SEC investigation over compounded semaglutide disclosures
- No confirmed brand-name manufacturer partnership
- Stock down 50%+ since January 2026 raising business continuity questions
Compare Hims & Hers With
See how Hims & Hers stacks up against other providers
About Hims & Hers
Hims & Hers is a major national telehealth provider founded in 2017 in San Francisco. They offer compounded injectable GLP-1 weight loss medications and serve both men (Hims) and women (Hers) with personalized health and wellness solutions.
Important: Hims is currently facing significant regulatory and legal challenges related to their compounded GLP-1 business. See “Recent News” below for details.
How It Works
- Online Consultation - Complete an async health assessment
- Provider Review - Licensed clinicians evaluate your eligibility
- Choose Your Plan - Select from available injectable options
- Home Delivery - Medication ships with free shipping and cold chain handling
Pricing (March 2026)
| Plan | Price | Medication |
|---|---|---|
| GLP-1 Injectable - 6 Month | $199/mo | Compounded Semaglutide (paid upfront) |
| GLP-1 Injectable Monthly | $299/mo | Compounded Semaglutide (month-to-month) |
| Generic Liraglutide | $299/mo | FDA-approved generic GLP-1 |
Free consultations and shipping on all plans. HSA/FSA eligible.
No longer available:
- Compounded oral semaglutide pill (suspended Feb 2026)
- Compounded tirzepatide (FDA shortage resolved, no longer legally compoundable)
- Brand-name Wegovy (no confirmed Novo Nordisk partnership)
Recent News (March 2026)
- Novo Nordisk Lawsuit (Feb 9, 2026): Novo Nordisk sued Hims & Hers for patent infringement (US Patent 8,129,343) over compounded semaglutide products
- Compounded Oral Pill Pulled (Feb 7, 2026): Hims launched a $49/mo compounded semaglutide pill on Feb 5, but pulled it within days after FDA warnings and HHS referral to DOJ for potential FDCA violations
- SEC Investigation: Hims disclosed an SEC investigation into public disclosures regarding its compounded semaglutide business
- Stock Impact: Share price has fallen over 50% since January 2026, trading around $13-16
- Revenue Headwind: $65 million Q1 2026 revenue impact tied to compounded semaglutide changes
- UK Expansion: Launched Weight Loss Program in UK in December 2025
- Canadian Acquisition: Acquired Livewell (Canadian digital health platform)
Who Is This Best For?
- Patients comfortable with compounded (non-FDA-approved) injectable semaglutide
- Those looking for competitive compounded GLP-1 pricing
- Patients who understand and accept the current regulatory risks
The Bottom Line
Hims & Hers is facing a “triple threat” of SEC investigation, Novo Nordisk patent litigation, and FDA/DOJ enforcement action. While compounded injectable semaglutide remains available, the company’s oral semaglutide pill was pulled shortly after launch. Patients should monitor the regulatory situation closely and consider providers with confirmed manufacturer partnerships for greater stability.
Last updated: March 2026
Last verified: April 2026
Ready to try Hims & Hers?
Compare with other providers or visit their website to get started.